Skip to main content

Table 1 Population characteristics at baseline and comparison between cases (patients with DFR status) and their paired controls

From: Early persistence on therapy impacts drug-free remission: a case-control study in a cohort of Hispanic patients with recent-onset rheumatoid arthritis

  Study population, n = 209 Cases, n = 23 Controls, N = 46 p
Sociodemographic characteristics
 Years of agea 38.3 (27.2–48.3) 39 (25.5–44.2) 36.3 (27.9–46.6) 0.656
 Female sexb 183 (87.6) 18 (78.3) 36 (78.3) 1
 Years of formal educationa 12 (9–15) 12 (9–15) 11.5 (9–14) 0.5
 Medium-low SE statusb 188 (90) 20 (87) 39 (84.8) 1
RA-related characteristics
 Months of disease durationa 5.1 (3–6.8) 5.2 (2.5–7) 4.9 (2.9–7.1) 0.775
 RF (positive titers)b 173 (82.8) 13 (56.5) 33 (71.7) 0.280
 ACPA (positive titers)b 172 (82.3) 11 (47.8) 28 (60.9) 0.318
 Erosionsb 21 (10.1) 1 (4.3) 5 (10.9) 0.656
 DAS28a 5.8 (4.6–6.8) 5.3 (4.5–6.4) 5.6 (4.2–6.5) 0.990
 Swollen joint counta 13 (8–18) 10 (6–16) 11.5 (7.8–18) 0.389
 Tender joint counta 13 (7–18) 12 (6–18) 12 (7–16) 0.784
 ESR, mm/Ha 21 (10–39) 18 (13–31) 19 (7.5–35.3) 0.731
 CRP, mg/dLa 0.7 (0.2–2.5) 0.3 (0.1–1.5) 0.6 (0.2–2.4) 0.074
Patient-reported outcomes measures
 HAQ score (0–3)a 1.4 (0.9–2) 1.3 (0.8–1.8) 1.1 (0.4–1.8) 0.342
 SF36 physical-component score (0–100)a 35 (23.5–54.2) 30.7 (22.3–51.3) 44.7 (27.3–66.6) 0.044
 SF36 mental-component score (0–100)a 44.6 (29.7–59.4) 39.5 (28.8–66) 51.7 (37.3–68) 0.208
 Patient-overall disease-VASa 51 (28.5–74) 44 (18.5–68) 44.5 (23.8–73.8) 0.593
RA-related treatment
 With corticosteroidsb 109 (52.2) 9 (39.1) 18 (39.1) 1
 With DMARDsb 209 (100) 23 (100) 46 (100) NA
 DMARDs/patient 2 (1–2) 2 (1–2) 2 (1–2) 0.265
  1. SE socio-economic, RF rheumatoid factor, ACPA antibodies to citrullinated proteins, DAS28 Disease Activity Score (28 joints), ESR erythrocyte sedimentation rate, CRP C-reactive protein, VAS visual analog scale, HAQ Health Assessment Questionnaire, SF-36 Short Form 36 Items, DMARDs disease-modifying anti-rheumatic drugs
  2. aMedian (IQR)
  3. bNumber (%) of patients